Search Results - "Osumili, B"

The economic costs of mental health-related discrimination by Osumili, B., Henderson, C., Corker, E., Hamilton, S., Pinfold, V., Thornicroft, G., McCrone, P.

“…Objective To estimate and compare the economic costs of mental health‐related discrimination in the domains of health care, relationships and participation in…”
Get full text

The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes by Paczkowski, R., Poon, J. L., Cutts, K. N., Krucien, N., Osumili, B., de Oliveira, C. Piras, Hankosky, E. R., Perez-Nieves, M., Radawski, C., Gelhorn, H. L.

“…Introduction While there have been continued advances in insulin treatment for diabetes since the discovery of insulin 100 years ago, some unmet needs still…”
Get full text

CO43 Projecting Cardiovascular Benefits Associated With Tirzepatide's Effects on Cardiovascular Risk Factors in Patients With Type 2 Diabetes in France: A Simulation Study by Osumili, B., Debackere, N., Ludwig, L., Sharland, H.

Get full text

RWD41 Utilization Patterns of Glucagon-like Peptide Receptor Agonists in Patients with Type 2 Diabetes in France and Italy by Khare, S., Osumili, B., Debackere, N., Keapoletswe, K., Falato, S., Raoul, T., Coles, B.

Get full text

PDB6 Indirect Treatment Comparison (ITC) of ULTRA-RAPID Lispro Insulin (URLI) Versus FAST-Acting Insulin Aspart (FASTER ASPART) in Patients with Type 1 Diabetes (T1DM) by Osumili, B., Paczkowski, R., Spaepen, E., Liao, B., Tobian, J.

Get full text

PDB34 The PRIME Type 2 Diabetes MODEL: A New, Product-Independent MODEL to Evaluate LONG-TERM Clinical and Cost Outcomes in Type 2 Diabetes by Valentine, W., Norrbacka, K., Boye, K., Osumili, B., Pollock, R.

Get full text

PCR5 The Impact of Substantial Improvements in HBA1C and Weight Loss on the Medication Preferences of People with Type 2 Diabetes by Gelhorn, H., Osumili, B., Brown, K., Ross, M., Schulz, A., Fernandez, G., Boye, K.

Get full text

POSB159 Comparing Modeled Outcomes with Published Studies in the Japanese Setting: A Validation Analysis with the Prime Type 2 Diabetes Model by Valentine, W, Boye, K, Norrbacka, K, Osumili, B, Pollock, R, Iwahori, T

Get full text

PDB46 A Best-Worst Scaling Preference Study: The Mealtime Insulin Experience for People with Diabetes in US and UK by Paczkowski, R., Poon, J.L., Cutts, K., Osumili, B., Piras de Oliveira, C., Hankosky, E.R., Gelhorn, H.

Get full text

Nasal Glucagon Saves Professional Emergency Medical (EM) Costs Versus Intramuscular Glucagon —A Us Based Cost-Offset Model by Bajpai, S, Poehlmann, J, Osumili, B, Mitchell, B, Valentine, WJ

Get full text

PDB56 - Nasal Glucagon Saves Professional Emergency Medical (EM) Costs Versus Intramuscular Glucagon —A Us Based Cost-Offset Model by Bajpai, S, Poehlmann, J, Osumili, B, Mitchell, B, Valentine, WJ

Get full text

PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALY by Matza, L.S., Osumili, B., Stewart, K.D., Perez, M., Jordan, J., Biricolti, G., Romoli, E., Losi, S., Del Santo, S., Spaepen, E., Parola, G., Syrad, H., Boye, K.

Get full text

The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes by Gelhorn, Heather L, Osumili, Beatrice, Brown, Katelyn, Ross, Melissa M, Schulz, Andrea, Fernandez, Gabriela, Boye, Kristina S

“…To quantify the preferences of people with type 2 diabetes (T2D) for treatment attributes of a glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like…”
Get full text

Étude mondiale CRASH (Conversations and Reactions Around Severe Hypoglycaemia) Résultats de la cohorte française des adultes ayant un diabète de type 1 by Chevalier, N., Benabbad, I., Chartier, F., Mitchell, B., Spaepen, E., Osumili, B., Peyrot, M., Snoek, F.

“…Objectif Comprendre la gestion des hypoglycémies sévères (HS) des personnes ayant un diabète (PAD) et des aidants. Enquête auprès des PAD et aidants de ≥18 ans…”
Get full text